Tvardi Therapeutics Inc Financials
This page shows Tvardi Therapeutics Inc (TVRD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Tvardi Therapeutics Inc has an operating margin of -818.0%, meaning the company retains $-818 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -579.4% the prior year.
Tvardi Therapeutics Inc's revenue declined 66% year-over-year, from $21.0M to $7.1M. This contraction results in a growth score of 0/100.
With a current ratio of 3.06, Tvardi Therapeutics Inc holds $3.06 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Tvardi Therapeutics Inc generated -$60.9M in operating cash flow, capex of $1.0M consumed most of it, leaving -$62.0M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Tvardi Therapeutics Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Tvardi Therapeutics Inc generates $0.86 in operating cash flow (-$60.9M OCF vs -$70.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Tvardi Therapeutics Inc generated $7.1M in revenue in fiscal year 2024. This represents a decrease of 66.0% from the prior year.
Tvardi Therapeutics Inc's EBITDA was -$58.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 52.0% from the prior year.
Tvardi Therapeutics Inc generated -$62.0M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 34.4% from the prior year.
Tvardi Therapeutics Inc reported -$70.9M in net income in fiscal year 2024. This represents an increase of 40.2% from the prior year.
Tvardi Therapeutics Inc earned $-15.53 per diluted share (EPS) in fiscal year 2024. This represents an increase of 40.9% from the prior year.
Tvardi Therapeutics Inc held $31.6M in cash against $0 in long-term debt as of fiscal year 2024.
Tvardi Therapeutics Inc had 3M shares outstanding in fiscal year 2024. This represents a decrease of 43.3% from the prior year.
Tvardi Therapeutics Inc's operating margin was -818.0% in fiscal year 2024, reflecting core business profitability. This is down 238.6 percentage points from the prior year.
Tvardi Therapeutics Inc's net profit margin was -993.0% in fiscal year 2024, showing the share of revenue converted to profit. This is down 427.7 percentage points from the prior year.
Tvardi Therapeutics Inc invested $32.8M in research and development in fiscal year 2024. This represents a decrease of 69.8% from the prior year.
Tvardi Therapeutics Inc invested $1.0M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 56.0% from the prior year.
TVRD Income Statement
| Metric | Q3'25 | Q3'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M+17.2% | $960K-62.6% | $2.6M+76.6% | $1.5M-43.1% | $2.6M+157.9% | $991K-53.6% | $2.1M-28.9% | $3.0M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $3.6M-37.9% | $5.8M+1720.1% | $319K+165.8% | -$485K-110.1% | $4.8M-26.6% | $6.5M-70.3% | $22.0M-22.7% | $28.4M |
| SG&A Expenses | $2.3M-23.8% | $3.1M-33.9% | $4.6M-74.5% | $18.2M+1963.9% | $881K+35.5% | $650K-90.5% | $6.8M+3.5% | $6.6M |
| Operating Income | -$5.9M+33.0% | -$8.9M-271.7% | -$2.4M+85.0% | -$15.9M-179.4% | -$5.7M+21.0% | -$7.2M+75.8% | -$29.7M+9.0% | -$32.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | -$32K-190.9% | -$11K | $0+100.0% | -$398K | $0 | $0 | $0 | $0 |
| Net Income | -$5.5M-232.6% | $4.2M+143.5% | -$9.6M+82.3% | -$54.2M-882.7% | -$5.5M+21.0% | -$7.0M-66.0% | -$4.2M+87.0% | -$32.3M |
| EPS (Diluted) | $-0.59+41.0% | $-1.00+68.9% | $-3.22-557.1% | $-0.49 | $-2.14+21.0% | $-2.71+86.6% | $-20.24 | N/A |
TVRD Balance Sheet
| Metric | Q3'25 | Q3'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $39.0M-10.8% | $43.8M+12.3% | $38.9M+10.6% | $35.2M-31.4% | $51.3M-29.2% | $72.5M-19.5% | $90.1M-28.4% | $125.8M |
| Current Assets | $38.4M-10.9% | $43.1M-36.8% | $68.2M+115.3% | $31.7M-33.9% | $47.9M-25.0% | $63.9M-21.4% | $81.2M-30.1% | $116.2M |
| Cash & Equivalents | $21.4M+3.7% | $20.6M-39.7% | $34.2M+8.2% | $31.6M-14.7% | $37.1M-24.7% | $49.2M+4.8% | $47.0M-9.2% | $51.8M |
| Inventory | N/A | N/A | $900K0.0% | $900K+44.0% | $625K-62.0% | $1.6M-40.0% | $2.7M-2.8% | $2.8M |
| Accounts Receivable | N/A | N/A | $1.2M+202.0% | $407K-6.4% | $435K+21.2% | $359K-79.1% | $1.7M-37.9% | $2.8M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $11.2M+3.1% | $10.8M-92.2% | $139.6M+10.5% | $126.3M-2.7% | $129.8M-10.8% | $145.6M-6.9% | $156.3M-16.8% | $187.9M |
| Current Liabilities | $11.0M+3.4% | $10.7M+790.6% | $1.2M-88.4% | $10.4M+3.3% | $10.0M-27.8% | $13.9M-7.9% | $15.1M-41.0% | $25.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $27.9M-15.4% | $32.9M+132.7% | -$100.6M-10.4% | -$91.1M-16.1% | -$78.5M-7.4% | -$73.1M-10.4% | -$66.2M-6.6% | -$62.1M |
| Retained Earnings | -$103.2M-5.7% | -$97.6M+87.2% | -$760.5M-724.5% | -$92.2M+87.7% | -$747.9M-1.7% | -$735.5M-2.8% | -$715.4M-4.5% | -$684.7M |
TVRD Cash Flow Statement
| Metric | Q3'25 | Q3'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.3M+52.0% | -$8.9M-88.9% | -$4.7M+90.1% | -$47.4M-612.9% | -$6.7M-128.2% | $23.6M+177.6% | -$30.5M-75.3% | -$17.4M |
| Capital Expenditures | $21K | N/A | N/A | $0 | $0-100.0% | $210K-74.9% | $836K-59.3% | $2.1M |
| Free Cash Flow | -$4.5M | N/A | N/A | -$47.4M-612.9% | -$6.7M-128.4% | $23.4M+174.9% | -$31.3M-61.1% | -$19.4M |
| Investing Cash Flow | $5.3M | N/A | N/A | $5.0M+100.0% | $2.5M-83.6% | $15.3M-41.1% | $26.0M+185.9% | -$30.2M |
| Financing Cash Flow | -$322K-101.5% | $22.0M+2088.7% | $1.0M+128.0% | -$3.6M-25578.6% | -$14K-102.0% | $690K+200.7% | -$685K-101.9% | $36.5M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TVRD Financial Ratios
| Metric | Q3'25 | Q3'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -586.9%-200.3pp | -386.7%-293.8pp | -92.9%+997.1pp | -1090.0%-868.0pp | -222.1%+502.6pp | -724.6%+664.9pp | -1389.5%-304.1pp | -1085.5% |
| Net Margin | -581.8%-202.1pp | -379.7%-6.8pp | -372.9%+3350.6pp | -3723.5%-3507.8pp | -215.7%+488.1pp | -703.8%-507.0pp | -196.8%+879.6pp | -1076.5% |
| Return on Equity | N/A | 12.7% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -14.2%-23.7pp | 9.5%+34.1pp | -24.6%+129.3pp | -153.9%-143.2pp | -10.7%-1.1pp | -9.6%-5.0pp | -4.7%+21.0pp | -25.7% |
| Current Ratio | 3.48-0.6 | 4.04-7.8 | 11.86+8.8 | 3.06-1.7 | 4.77+0.2 | 4.59-0.8 | 5.38+0.8 | 4.54 |
| Debt-to-Equity | 0.40+0.1 | 0.33+1.7 | -1.390.0 | -1.39+0.3 | -1.65+0.3 | -1.99+0.4 | -2.36+0.7 | -3.03 |
| FCF Margin | -400.8% | N/A | N/A | -3260.8%-3000.4pp | -260.4%-2624.2pp | 2363.9%+3829.4pp | -1465.5%-819.0pp | -646.5% |
Note: Shareholder equity is negative (-$91.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Tvardi Therapeutics Inc's annual revenue?
Tvardi Therapeutics Inc (TVRD) reported $7.1M in total revenue for fiscal year 2024. This represents a -66.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Tvardi Therapeutics Inc's revenue growing?
Tvardi Therapeutics Inc (TVRD) revenue declined by 66% year-over-year, from $21.0M to $7.1M in fiscal year 2024.
Is Tvardi Therapeutics Inc profitable?
No, Tvardi Therapeutics Inc (TVRD) reported a net income of -$70.9M in fiscal year 2024, with a net profit margin of -993.0%.
What is Tvardi Therapeutics Inc's earnings per share (EPS)?
Tvardi Therapeutics Inc (TVRD) reported diluted earnings per share of $-15.53 for fiscal year 2024. This represents a 40.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Tvardi Therapeutics Inc's EBITDA?
Tvardi Therapeutics Inc (TVRD) had EBITDA of -$58.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Tvardi Therapeutics Inc's operating margin?
Tvardi Therapeutics Inc (TVRD) had an operating margin of -818.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Tvardi Therapeutics Inc's net profit margin?
Tvardi Therapeutics Inc (TVRD) had a net profit margin of -993.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Tvardi Therapeutics Inc's free cash flow?
Tvardi Therapeutics Inc (TVRD) generated -$62.0M in free cash flow during fiscal year 2024. This represents a 34.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Tvardi Therapeutics Inc's operating cash flow?
Tvardi Therapeutics Inc (TVRD) generated -$60.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Tvardi Therapeutics Inc's total assets?
Tvardi Therapeutics Inc (TVRD) had $35.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Tvardi Therapeutics Inc's capital expenditures?
Tvardi Therapeutics Inc (TVRD) invested $1.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Tvardi Therapeutics Inc spend on research and development?
Tvardi Therapeutics Inc (TVRD) invested $32.8M in research and development during fiscal year 2024.
How many shares does Tvardi Therapeutics Inc have outstanding?
Tvardi Therapeutics Inc (TVRD) had 3M shares outstanding as of fiscal year 2024.
What is Tvardi Therapeutics Inc's current ratio?
Tvardi Therapeutics Inc (TVRD) had a current ratio of 3.06 as of fiscal year 2024, which is generally considered healthy.
What is Tvardi Therapeutics Inc's debt-to-equity ratio?
Tvardi Therapeutics Inc (TVRD) had a debt-to-equity ratio of -1.39 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Tvardi Therapeutics Inc's return on assets (ROA)?
Tvardi Therapeutics Inc (TVRD) had a return on assets of -201.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Tvardi Therapeutics Inc's cash runway?
Based on fiscal year 2024 data, Tvardi Therapeutics Inc (TVRD) had $31.6M in cash against an annual operating cash burn of $60.9M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Tvardi Therapeutics Inc's debt-to-equity ratio negative or unusual?
Tvardi Therapeutics Inc (TVRD) has negative shareholder equity of -$91.1M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Tvardi Therapeutics Inc's Piotroski F-Score?
Tvardi Therapeutics Inc (TVRD) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Tvardi Therapeutics Inc's earnings high quality?
Tvardi Therapeutics Inc (TVRD) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Tvardi Therapeutics Inc?
Tvardi Therapeutics Inc (TVRD) scores 25 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.